CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital through a new convertible debt offering. The gene-editing firm said it intends to ...

CRISPR Therapeutics AG (NASDAQ:CRSP) also received a rating update from JPMorgan on February 16. The firm cut the price ...

Casgevy is starting to build some serious sales momentum. CRISPR Therapeutics also has a deep pipeline and healthy funding. The stock requires patience, but there is a visible path to a bright future.

Cathie Wood’s ARK Invest added to several beaten-down technology and biotech names while trimming positions elsewhere. The investment manager made a notable purchase in gene-editing company CRISPR ...

ARK Invest deployed over $10M in CRISPR Therapeutics and PayPay Corp on March 12, while cutting positions in Teradyne and Ionis Pharmaceuticals.